ZVRA
Zevra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.40
−1.12%Aug 6, 2026, 01:37 UTC
Zevra Therapeutics reported Q2 2026 earnings of $0.25 per share, surpassing the Zacks Consensus Estimate of $0.08 per share, and compared to $1.21 per share a year ago.
Aug 3, 2026, 11:30 UTC
Zevra Therapeutics announced the publication of four-year real-world data from its U.S. Early Access Program evaluating MIPLYFFA (arimoclomol) in Niemann-Pick Disease Type C (NPC).
Source:Jul 24, 2026, 11:30 UTC
The CHMP of the EMA adopted a negative opinion on the Marketing Authorization Application for arimoclomol for Niemann-Pick disease type C, and Zevra Therapeutics plans to request a re-examination.
Jun 11, 2026, 12:30 UTC
Zevra Therapeutics' Chief Medical Officer Adrian Quartel is stepping down effective July 3, 2026, due to personal reasons.
Source: